TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06497517
Drug: GSK5464714- Camlipixant
Normalized name: Camlipixant
DrugBank: Camlipixant (DB19217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK5464714- Camlipixant will be administered
Study: NCT06572618
Drug: Nemtabrutinib
Normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05910190
Drug: Use of buprenorphine with FAO > 30 OME
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive buprenorphine with concurrent FAO \>30 OME and be assessed for withdrawal, pain, and other symptoms.
Study: NCT00538811
Drug: interferon alpha-2b, ribavirin, interferon-gamma,
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00538811
Drug: interferon alpha-2b, ribavirin, amantadine
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05955261
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax will be given with each course of therapy. Patients with low-risk AML will receive four courses of therapy, intermediate-risk patients will receive five courses of therapy, and high-risk patients will receive two or three courses of therapy followed by hematopoietic stem cell transplantation.
Study: NCT05955261
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV over 30 minutes on days 1-5
Study: NCT00051662
Drug: efalizumab
Normalized name: Efalizumab
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05955261
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV over 30 minutes q12 hours on days 1-8 (16 doses)
Study: NCT05955261
Drug: Gemtuzumab Ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT05955261
Drug: Daunorubicin Hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV over 1 hour on days 1, 3, and 5
Study: NCT05955261
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV over 30 minutes on days 1-5
Study: NCT05955261
Drug: Idarubicin Hydrochloride
Normalized name: Idarubicin Hydrochloride
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV over 15 minutes on days 3-5
Study: NCT05955261
Drug: Mitoxantrone Hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV over 1 hour on days 2-4
Study: NCT05955261
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV over 1 hour on days 1-5
Study: NCT05955261
Drug: Gilteritinib
Normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PO on days 8-28 (21 doses)
Study: NCT05364424
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intravenous (IV) glofitamab for up to 3 cycles.
Study: NCT05364424
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive IV obinutuzumab on Cycle 1 Day 1.
Study: NCT05364424
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive IV tocilizumab as necessary to manage cytokine release syndrome (CRS) events.
Study: NCT05364424
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive up to 2 doses of IV rituximab.
Study: NCT05364424
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive IV ifosfamide for up to 3 cycles.
Study: NCT05364424
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive IV carboplatin for up to 3 cycles.
Study: NCT05364424
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive IV etoposide for up to 3 cycles.
Study: NCT04578652
Drug: Metformin 850 mg oral tablet bid
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily).
Study: NCT06522594
Drug: Esmolol
Normalized name: Esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A vey cardioselective, short-acting betablocker, with an ultra-short half life time.
Study: NCT00268255
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05686044
Drug: Buntanetap/Posiphen
DrugBank: Posiphen (DB15317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC (vegetarian source) capsule shells
Study: NCT06567600
Drug: Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Gemcitabine and Cisplatin Chemotherapy:~Gemcitabine 500 mg/m2 Cisplatin 12.5 mg/m2 on day 1 and day 8 of each 21-day cycle for up to eight cycles~PD-1/PD-L1Antibody:~Pembrolizumab 200mg on day 1 of each 21-day cycle Durvalumab 1500 mg on day 1 of each 21-day cycle After completion of gemcitabine and cisplatin, 200mg of Pembrolizumab or 1500 mg of Durvalumab may administer once every 3 or 4 weeks until clinical or imaging (per RECIST v1.1) disease progression or until unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria were met.
Study: NCT06276504
Drug: Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab administration at D0, M1 and M2
Study: NCT04197219
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg IV day 1 of each cycle every 21 days
Study: NCT04197219
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg PO BID continuously
Study: NCT04963985
Drug: Tafamidis Pill
Normalized name: tafamidis Pill
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral
Study: NCT06654531
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Under a sterile technique, spinal anesthesia will be carried out using a 22-G Quincke spinal needle after skin infiltration with 2% lidocaine 3 ml a t the L3-L4 level, a midline approach in the sitting position, and then in the supine position.~Th e time of spinal injection will be considered time zero (T0). The I.V drug regimen will be started according to the group to which patients will be assigned.patients will receive intrathecal 15 mg hyperbaric bupivacaine together with 5 μg Dexmedetomidine in group 2
Study: NCT06444191
Drug: Rilzabrutinib
Normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilzabrutinib tablet(s) administered orally
Study: NCT04710888
Drug: use of basil extract gel in treatment of aphthus ulcer
DrugBank: Basil (DB10829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study aimed to evaluate the efficacy of basil extract (Ocimum basilicum) in the treatment of aphthous ulcers
Study: NCT04986436
Drug: HS-10360
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple dose(s) of HS-10360
Study: NCT06003348
Drug: Potassium Citrate
Normalized name: Potassium Citrate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mEq Extended-release tablets for oral use
Study: NCT06571045
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
Study: NCT04201808
Drug: Tenofovir Alafenamide 25 MG
Normalized name: tenofovir alafenamide 25 MG
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will receive Tenofovir Alafenamide, 25mg PO, to treat chronic hepatitis B and their previous suboptimal response over the study duration of 48 weeks. Patients will be followed every 12 weeks for medication adherence, medication refill, and follow up as per standard of care.
Study: NCT05260528
Drug: Cytarabine and Idarubicin
Normalized name: cytarabine and daunorubicin
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction 1: Cytarabine 200 mg/m2 i.v. (continuously) d1-7 + Idarubicin 12mg/m2 d1, 2, 3 i.v (60 min)~Induction 2: Cytarabine 1500 mg/m2 i.v. q12h d1-3~Consolidation: Cytarabine 1500 mg/m2 i.v. q12h d1-3
Study: NCT05260528
Drug: CPX-315
Normalized name: CPX
DrugBank: DPCPX (DB12946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction 1:CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3,5~Induction 2: CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3~Consolidation therapy:CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine i.v. (90 min) d1,3
Study: NCT05865041
Drug: Farudodstat
Normalized name: Farudodstat
DrugBank: Farudodstat (DB16049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Farudodstat tablets administered orally
Study: NCT06650293
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation as vitamin D, 2 drops i.e., 800 IU daily for 5 days.
Study: NCT06405633
Drug: WVE-006
Normalized name: WVE 003
DrugBank: WVE-003 (DB17870)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNA editing oligonucelotide
Study: NCT05732532
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mL of bupivacaine 0.5% (5 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
Study: NCT05732532
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mL of lidocaine 1% (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
Study: NCT05732532
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 mL of dexamethasone (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
Study: NCT00669123
Drug: Chondroitin sulphate
Normalized name: Chondroitin sulphate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulphate 800 mg/day
Study: NCT04827576
Drug: Magrolimab
Normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT04827576
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously, 75 mg/m\^2 on Day 1 of each cycle
Study: NCT01481532
Drug: Crotoxin
Normalized name: PICROTOXIN
DrugBank: Picrotoxin (DB00466)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra patient dose escalation
Study: NCT02577094
Drug: 90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 injections of 90Y-DOTA- hLL2 IgG- hLL2 IgG at day -21 and day -14. (The 2 drugs are mixted in the same infusion)
Study: NCT02577094
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
Study: NCT02577094
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
Study: NCT00002329
Drug: Celgosivir hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Celgosivir (DB06580)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06561620
Drug: Befotertinib
Normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befotertinib is a novel, selective oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor.
Study: NCT05533580
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The experimental group was sedated with remimazolam.
Study: NCT05533580
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group was sedated with propofol.
Study: NCT00989872
Drug: EDP-322
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06653348
Drug: Ticagrelor 60 + Aspirin
Normalized name: ticagrelor 60 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month and then ticagrelor 60 mg BID plus ASA 80 mg daily until the end of month 3.
Study: NCT06653348
Drug: Ticagrelor 90 + aspirin
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month.
Study: NCT05689983
Drug: Symptom-driven budesonide/formoterol combination
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In this intervention, patients will be assigned to a symptom-driven budesonide/formoterol combination therapy (Symbicort) and their adherence to this regimen will be assessed and compared to patients taking a standard therapy with a maintenance inhaled corticosteroid and as needed short-acting beta-agonist.
Study: NCT04888377
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant's mothers were administered 81mg of Aspirin throughout their pregnancy with the participant.
Study: NCT05726110
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05726110
Drug: Homoharringtonine
Normalized name: Homoharringtonine
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given per standard of care
Study: NCT05726110
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given per standard of care
Study: NCT05726110
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given per standard of care
Study: NCT05726110
Drug: Granulocyte Colony-Stimulating Factor
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given per standard of care
Study: NCT05726110
Drug: Aclacinomycin
Normalized name: Aclacinomycin
DrugBank: Aklavine (DB19070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given per standard of care
Study: NCT06060327
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Giving oxytocin only, or oxytocin in addition to Tranexamic acid, Misoprostol or Carbetocin the mentioned doses and by the mention routes, then comparing the estimated blood loss in each group.
Study: NCT05279807
Drug: Zofenopril
Normalized name: Zofenopril
DrugBank: Zofenopril (DB13166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.
Study: NCT05279807
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
Study: NCT05003752
Drug: Goserelin 10.8 mg
Normalized name: goserelin 10.8 MG
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Androgen deprivation will be administered based on NCCN guidelines in patients with unfavorable intermediate/high risk organ-confined prostate cancer
Study: NCT06072612
Drug: Interferon infiltration of the inoculation site
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.
Study: NCT06072612
Drug: Retifanlimab
Normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.
Study: NCT04739202
Drug: Atezolizumab + Ipatasertib
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.
Study: NCT04739202
Drug: Atezolizumab + Bevacizumab
Normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.
Study: NCT05367089
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Way of administration: oral capsules. One capsule at the same day of the week.~Dosage:~As treatment for active RVVC- in the first week on day 1 one capsule 150 mg Fluconazole, on day 4 one capsule 150 mg Fluconazole and on day 7 one capsule 150 mg Fluconazole.~As prophylaxis to prevent a new RVVC episode: one capsule Fluconazol 150 mg per week for a duration of 6 months.
Study: NCT06017037
Drug: Citalopram 20mg
Normalized name: Escitalopram 20mg Oral tablet
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram 20mg tablets, encapsulated to aid blinding. To take per oral once daily for 7-9 days
Study: NCT05102162
Drug: Cefepime, Meropenem, or Piperacillin/Tazobactam
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
Study: NCT05901831
Drug: Finerenone
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose A, Dose B, oral
Study: NCT00043797
Drug: Lidorestat (IDD 676)
Normalized name: Lidostat
DrugBank: Lidorestat (DB07063)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001062
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04527393
Drug: Individualized oral morphine
Normalized name: morphine Oral Tablet
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analgesic effectiveness is assessed using the Faces Scale by the parents every four hours from postoperative Day 1 to Day 10 (eg: 8:00, 12:00, 16:00, and 20:00, each day).~If the Faces Scale score \> 6, the child receive rescue oral morphine analgesia. Patients with positive results of fentanyl test receive oral morphine 100μg/kg per dose, while patients with negative results receive oral morphine 500μg/kg per dose.
Study: NCT04527393
Drug: Conventional oral morphine
Normalized name: morphine Oral Tablet
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analgesic effectiveness is assessed using the Faces Scale by the parents every four hours from postoperative Day 1 to Day 10 (eg: 8:00, 12:00, 16:00, and 20:00, each day).~If the Faces Scale score \> 6, the child receive rescue oral morphine analgesia. Patients receive oral morphine 200μg/kg per dose.
Study: NCT05478356
Drug: low-dose atropine eye drops
Normalized name: ethinyl estradiol
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low-dose atropine eye drops
Study: NCT06541509
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 overweight patients with heart failure will be enrolled, including 5 patients with heart failure with preserved ejection fraction (HFpEF) and 5 patients with heart failure with reduced ejection fraction (HFrEF). The diagnosis of HFpEF and HFrEF will be based on the most recent European Society of Cardiology guidelines for the diagnosis and treatment of heart failure.~After their baseline blood sample collections, all participants will receive once-weekly subcutaneous semaglutide (Ozempyc, Novo Nordisk A/S Bagsvaerd, Denmark) at a dose of 0.25 mg for 2 weeks, 0.5 mg for 2 weeks, and then 1.0 mg for a period of 12 weeks. At the end of the 3-month and 4-month period, blood sample collections will be repeated. All blood samples will be sent to Stanford Cardiovascular Institute for further analyses. At baseline, and again at 4 months transthoracic echocardiography, 6-minute walk test, and body composition assessment will be performed.
Study: NCT06362707
Drug: Fasudil
Normalized name: fasudil
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: A ROCK inhibitor approved for treating vasospasms following subarachnoidal bleeding in Japan and China. Dosage: Participants will undergo a 2-week titration period at 60 mg daily before escalating to a maintenance dose of 120 mg daily.
Study: NCT05518409
Drug: Donepezil for patients with AD and DLB
Normalized name: donepezil and memantine
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects in AD and DLB groups were given donepezil at an initial dose of 5mg and then increased to 10mg one month later. Lasting for 1 year.
Study: NCT04947085
Drug: Ketamine via Intravenous
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine administration in sub-dissociative doses